Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • News

What’s Going On With Pfizer Stock Today?

By Vandana Singh
February 1, 10:21 AM
Pfizer stock update: Q4 earnings beat expectations with adjusted EPS of $0.10, while FY2023 shows a 72% YoY decline. Explore 2024 R&D plans and recent program discontinuations.

PFE

Read More
1 minute read
  • Biotech
  • Financing
  • General
  • Health Care
  • News

What’s Going On With Cancer-Focused Corbus Pharmaceuticals Stock Today?

By Vandana Singh
February 1, 10:18 AM
Corbus Pharmaceuticals announces a $82.2M public offering at $19.00 per share. Explore latest updates on CRB-701 clinical study.

CRBP

Read More
2 minute read
  • Biotech
  • Cannabis
  • Events
  • FDA
  • Government
  • Health Care
  • Psychedelics

FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000

By Lara Goldstein
January 31, 8:05 PM
FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address issues in drug development.

JNJ

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Drug Wholesale Firm Cencora Starts 2024 With Strong Growth, Lifts Annual Forecast On Commercial COVID-19 Vaccine Distribution

By Vandana Singh
January 31, 2:42 PM
Cencora reports Q1 2024 results with adjusted EPS at $3.28 and revenue of $72.3 billion. Explore the company's fiscal year 2024 guidance and growth projections.

COR

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • News

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer’s, Shifts Focus On Newer Medicines

By Vandana Singh
January 31, 1:10 PM
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.

BIIB

Read More
2 minute read
  • Earnings
  • Equities
  • General
  • Guidance
  • Health Care
  • News

Generic Drug Player Teva Pharma To Divest Its Active Pharmaceutical Ingredient Business, Q4 Earnings Surpass Estimates

By Vandana Singh
January 31, 11:14 AM
Teva Pharmaceutical surpasses Q4 2023 sales expectations, reporting $4.46 billion. Teva plans to divest API business for revenue optimization. Outlook for FY 2024.

TEVA

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

Medical Equipment Maker Thermo Fisher Scientific Clocks 7% Decline In Q4 Organic Sales, Issues Subdued Annual Outlook

By Vandana Singh
January 31, 10:49 AM
"Thermo Fisher Scientific surpasses Q4 revenue expectations at $10.89B, down 5% YoY. Analytical Instruments Segment rises 8.5%. Financial highlights and 2024 revenue guidance.

TMO

Read More
2 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine

By Vandana Singh
January 31, 9:50 AM
GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections.

GSK

Read More
3 minute read
  • Analyst Color
  • Earnings
  • Equities
  • General
  • Health Care
  • Large Cap
  • Markets
  • News

Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won’t Floor Novo, Eli Shares

By Neil Dennis
January 31, 9:49 AM
Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market.

AZN

Read More
1 minute read
  • Exclusives
  • General
  • Health Care
  • M&A
  • Market-Moving Exclusives
  • News

EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic

By Vandana Singh
January 31, 9:45 AM
Orgenesis to acquire full ownership of Octomera & Metalmark to receive royalty & proceeds in exchange. Shift to decentralized production supported by regulators.

ORGS

Posts pagination

Previous 1 … 66 67 68 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service